NGS Cancer Hotspot Panel


Accredited testing is now available using the AmpliSeq for Illumina Cancer Hotspot Panel v2. 

The following genes are partially sequenced in this test: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL

For more information about the coverage of the genes and transcripts included in this assay please click this link

NGS Cancer Hotspot Panel Testing at WRGL

NGS testing is performed using a commercially available kit from Illumina ( followed by analysis on a iSeq 100 Sequencing System.  This is a targeted NGS assay used to sequence ~2,800 COSMIC somatic mutations across hotspot regions of 50 genes with known associations to cancer.


Cost, Sample Requirements & Turnaround Times



Cost NZD*

Sample Requirements

Current TAT

Cancer Hotspot Panel $693 + GST

NGS testing can be performed on bone marrow, leukaemic blood and FFPE samples

Bone Marrow: 1-10ml in EDTA

Leukaemic Blood: 4-10ml in EDTA

FFPE sample:  please provide 2-3 slides (minimum) cut at 4 microns along with an H&E slide with the area of interest circled

4 weeks

*No direct charge for the central region DHBs covered by the Crown Funding Agreement

NGS Cancer Hotspot Panel


Wellington Regional Genetics Laboratory (WRGL) provides a comprehensive, integrated diagnostic cytogenetic and molecular genetic testing service

btn find


(04) 918-5352

Please note that genetic test results are only released directly to the referring clinician and not to patients